A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children (ICON3)
Primary Objective
To determine if the proportion of patients with a platelet response is significantly greater in patients with newly diagnosed ITP treated with eltrombopag than those treated with standard first-line treatments
Details
Age
Child
Type of Study
Treatment
Scope
National
Locations
Childrens Hospital Colorado
Principal Investigator
Taizo Nakano, MD
Study ID
Protocol Number: 18-1963
More information available at ClinicalTrials.gov: NCT03939637
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers